AZ COVID Antibody Treatment Fails to Show Significant Effect in Phase 3 Trial

COVID-19 vaccine developed by AstraZeneca.
[Image source=Reuters Yonhap News]

[Asia Economy Reporter Donghyun Choi] AstraZeneca (AZ)'s COVID-19 antibody treatment (AZD7442) has been found to have no significant therapeutic effect in clinical trials.

According to foreign media including Bloomberg on the 15th (local time), AstraZeneca announced that the phase 3 trial results showed that the COVID-19 symptom suppression effect of the treatment candidate 'AZD7442' was 33%.

AZD7442 uses laboratory-produced antibodies rather than antibodies extracted from COVID-19 recovered patients. This trial was conducted on 1,121 people who had been in contact with COVID-19 patients within 8 days.

In 59 regions in the UK and the US, unvaccinated volunteers aged 18 and over were given two injections of 300 mg of AZD7442, and the occurrence of COVID-19 symptoms was compared with a placebo group (given a fake drug).

As a result, those who received the treatment showed 33% fewer COVID-19 symptoms compared to the placebo group. Bloomberg reported, "This is not considered statistically significant."

AstraZeneca began developing the COVID-19 antibody treatment last June with about 28 billion KRW in funding from a US government agency.

This content was produced with the assistance of AI translation services.